Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer

PURPOSE: The presence of extensive ductal carcinoma in situ (DCIS) adjacent to HER2-positive invasive breast cancer (IBC) is often a contra-indication for breast-conserving surgery, even in case of excellent treatment response of the invasive component. Data on the response of DCIS to neoadjuvant sy...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Main Authors: Groen, Emma J., van der Noordaa, Marieke E. M., Schaapveld, Michael, Sonke, Gabe S., Mann, Ritse M., van Ramshorst, Mette S., Lips, Esther H., Vrancken Peeters, Marie-Jeanne T. F. D., van Duijnhoven, Frederieke H., Wesseling, Jelle
Formato: Artigo
Idioma:Inglês
Publicado: Springer US 2021
Assuntos:
Epidemiology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8302531/
https://ncbi.nlm.nih.gov/pubmed/33945043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-021-06235-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares